These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29091195)

  • 1. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
    Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D
    J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Bowker KE
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
    Vidaillac C; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.
    Lahiri SD; McLaughlin RE; Whiteaker JD; Ambler JE; Alm RA
    J Antimicrob Chemother; 2015 Sep; 70(9):2488-98. PubMed ID: 26045529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.
    Sader HS; Rhomberg PR; Doyle TB; Flamm RK; Mendes RE
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30257898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
    Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
    J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
    Keel RA; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4028-32. PubMed ID: 21670184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.
    Biedenbach DJ; Alm RA; Lahiri SD; Reiszner E; Hoban DJ; Sahm DF; Bouchillon SK; Ambler JE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):343-7. PubMed ID: 26503659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus.
    Lee H; Yoon EJ; Kim D; Kim JW; Lee KJ; Kim HS; Kim YR; Shin JH; Shin JH; Shin KS; Kim YA; Uh Y; Jeong SH
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
    Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O
    Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
    Van Wart SA; Ambrose PG; Rubino CM; Khariton T; Riccobene TA; Friedland HD; Critchley IA; Bhavnani SM
    Antimicrob Agents Chemother; 2014; 58(2):885-91. PubMed ID: 24277021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
    Drusano GL
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.
    Urbán E; Stone GG
    Clin Microbiol Infect; 2019 Nov; 25(11):1429.e1-1429.e4. PubMed ID: 30980925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
    Sader HS; Flamm RK; Farrell DJ; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Jul; 70(7):2053-6. PubMed ID: 25814163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.
    Mendes RE; Tsakris A; Sader HS; Jones RN; Biek D; McGhee P; Appelbaum PC; Kosowska-Shick K
    J Antimicrob Chemother; 2012 Jun; 67(6):1321-4. PubMed ID: 22398650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.